Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 11, pp 3593–3599 | Cite as

Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center

  • Elliot A. AsareEmail author
  • Angelica Silva-Figueroa
  • Kenneth R. Hess
  • Naifa Busaidy
  • Paul H. Graham
  • Elizabeth G. Grubbs
  • Jeffrey E. Lee
  • Michelle D. Williams
  • Nancy D. Perrier
Endocrine Tumors

Abstract

Background

Development of distant metastases (DM) is associated with markedly decreased survival in parathyroid carcinoma (PC). We sought to identify factors associated with development of DM and to quantify the effect that development of DM had on overall survival (OS).

Methods

Patients with surgically resected local/regional PC treated or surveilled at a tertiary-referral cancer hospital from 1980 to 2017 were included. We assessed the association between biochemical and clinicopathologic factors (preoperative parathyroid hormone (PTH) levels, sex, race, age, preoperative serum calcium levels, serum calcium levels at 6 months postop, tumor size, and extent of resection) with the development of DM. We also assessed the effect of development of DM on OS.

Results

Seventy-five patients with PC were assessed; 17 (22.7%) developed DM at a median follow-up of 77 months. The cumulative incidence of DM in the cohort was 20, 30, and 38% at 5, 10, and 20 years respectively. Tumor size > 3.2 cm based on recursive partitioning analysis was the only significant predictor for development of DM (hazard ratio (HR) = 3.51; 95% confidence interval [CI] 1.04–11.91; p = 0.04). Median OS for the entire cohort was 17 years compared with 40 months for the cohort who developed DM. The HR for death after distant metastasis was 9.6 (95% CI 4.2–22.3; p < 0.0001).

Conclusions

Development of distant metastasis during surveillance is associated with decreased OS, including late recurrences. Primary tumor size should be considered in future interval surveillance and development of treatment algorithms.

Notes

Disclosures

All authors have no financial disclosures.

References

  1. 1.
    Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.CrossRefGoogle Scholar
  2. 2.
    Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86.CrossRefGoogle Scholar
  3. 3.
    Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16:724–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22:3990-5.CrossRefGoogle Scholar
  5. 5.
    Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.CrossRefPubMedGoogle Scholar
  6. 6.
    DeLellis R, Heitz PU. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.Google Scholar
  7. 7.
    Silva-Figueroa AM, Hess KR, Williams MD, et al. Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg. 2017;224:980–7.CrossRefGoogle Scholar
  8. 8.
    Zhang H, Singer B. Recursive partitioning in the health sciences. New York: Springer; 1999.CrossRefGoogle Scholar
  9. 9.
    Hsu KT, Sippel RS, Chen H, et al. Is central lymph node dissection necessary for parathyroid carcinoma? Surgery. 2014;156:1336–41; discussion 1341.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Xue S, Chen H, Lv C, et al. Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients. Clin Endocrinol (Oxf). 2016;85:29–36.CrossRefPubMedGoogle Scholar
  11. 11.
    Villar-del-Moral J, Jimenez-Garcia A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156:1132–44.CrossRefPubMedGoogle Scholar
  12. 12.
    In H, Bilimoria KY, Stewart AK, et al. Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol. 2014;21:1520–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Christakis I, Bussaidy N, Clarke C, et al. Differentiating atypical parathyroid neoplasm from parathyroid cancer. Ann Surg Oncol. 2016;23:2889–97.CrossRefPubMedGoogle Scholar
  14. 14.
    Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer. 1999;86:378–80.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Elliot A. Asare
    • 1
    Email author
  • Angelica Silva-Figueroa
    • 2
    • 3
  • Kenneth R. Hess
    • 4
  • Naifa Busaidy
    • 5
  • Paul H. Graham
    • 1
  • Elizabeth G. Grubbs
    • 1
  • Jeffrey E. Lee
    • 1
  • Michelle D. Williams
    • 6
  • Nancy D. Perrier
    • 1
  1. 1.Department of Surgical OncologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Universidad Finis TerraeSantiagoChile
  3. 3.Department of Head and Neck SurgeryHospital Barros Luco-TrudeauSantiagoChile
  4. 4.Department of BiostatisticsUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  5. 5.Department of Endocrine Neoplasia and Hormonal DisordersUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA
  6. 6.Department of PathologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations